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Coexistence of MALT lymphoma with carcinomas was seen primarly 
in gastric lesions associated with H. Pylori infections. To our knowl-
edge only one case was reported with synchronous pulmonary adeno-
carcinoma and MALT type extranodal marginal zone lymphoma.
Case Report: A 49 years old male presented with back pain, weight 
loss and fatique. Chest x-ray revealed an increased density suggest-
ing a mass localized to superior zone of left lung. Systemic radiologic 
examination of the patient did not reveal any other mass lesion. Endo-
scopic examination of upper gastrointestinal system revealed gastric 
ulcer. The biopsy taken from the stomach and duodenum showed 
MALT lymphoma in both locations. He underwent an exploratory chest 
operation, during which a mass lesion comletely invading thorasic 
outlet and a second mass lesion located in apical segment of left upper 
lobe, seperated from the ﬁrst mass by a thickened pleura were noted. A 
frozen section diagnoses of malignant neoplasm was given for the mass 
lesion invading thorasic outlet. Therefore, this mass was exsized along 
with wedge resection of the second apical lung lesion. The exsized ﬁrst 
mass measured 5x4x0,7 cm, it was hard and gray to brown colored. 
The wedge resection covered with visceral pleura measured 8x5,5x 
2cm and contained an inﬁltrative hard, grayish white mass of 2 cm 
diameter without pleural involvement.These two tumors,one of which 
was primarily localized in pleura with limited extension into the lung 
parenchyma and the other mainly localized in the lung parenchyma 
had different morphologic and immune phenotypic features. Light 
microscopy of the tumor involving mainly pleura showed a malignant 
epithelial tumor with mainly diffuse patern with focal papillary areas. 
The differential diagnoses of this tumor included primary or metastatic 
adenocarcinoma and epithelial mesothelioma. Mucicarmine stain was 
negative while PAS and D-PAS stains were positive in some tumor 
cells. Tumor cells were pankeratin and vimentin positive, TTF-1, CK7, 
CK 5/6, CK20, CEA, calretinin, NSE, synaptophysin and chromogranin 
negative. There was focal CD15 positivity. Although CK7 and TTF-1 
were negative, these morphologic, histochemical and immunohisto-
chemical features suggested that this tumor might represent an undiffer-
entiated large cell or poorly differentiated pulmonary adenocarcinoma. 
The second tumor localized in lung parenchyma was well differentiated 
adenocarcinoma with mucicarmine positive intracytoplasmic mucine 
secretion. It had CK7, TTF-1 positive and vimentin, CK 5/6 and CK20 
negative immunophenotype. This tumor was intimately associated with 
diffuse neoplastic lymphocytic inﬁltration. Neoplastic lymphocytic 
cells had a monocytoid appearance with formation of occasional lym-
phoepithelial lesions. Lymphocytic tumor cells CD20 positive, CD5, 
CD10, CD23, CD3 and cyclinD1 negative immunophenotype. Because 
of these features, a diagnoses of MALT lymphoma was given. 
To the best of our knowledge our case is the ﬁrst one that presented 
with two different lung carcinomas which had different morphologic 
and immunophenotypic features, one of which was associated with 
multisystemic (lung, stomach,duodenum) extranodal marginal zone 
lymphoma of MALT type.
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Clinicopathological study of bronchogenic carcinoma - a study of 
303 cases
Uddin, Mokhles 
Dhaka Medical College Hospital, Dhaka, Bangladesh
Subjects: 303 patients of bronchogenic carcinoma in the Department 
of Radiotherapy. Dhaka Medical College Hospital. Dhaka from 1st 
January 2000 to 31st December 2005. 
Settings: Department of Radiotherapy, Dhaka Medical College Hospital
Main Outcome Measures: This study reveals a general idea of certain 
clinicopathological aspects of bornchogenic carcinoma prevailing 
amongst the population of Bangladesh.
Results: Males (87.79%) suffered more than females (12.2%) their 
ratio was 7.19:1. Majority of the patients were of elderly age group 
with peak occurrence between 50 and 59 years. More than 90% of the 
patients were smoker. 86.47% chewed betel leaf 68.65% used tea and 
only 19 (6.27%) were alcoholic. More than 60% of the patients were 
lower socioeconomic class and others from middle class family. Ap-
proximately 40% of the patients were illiterate. 37.29% had primary 
education. 12.54% secondary school education. 5.96% higher second-
ary and only 4.62% graduate and above.
Cough (77.89%) was the commonest presenting symptom followed 
by chest pain (66%). Dyspnoea (44.55%). haemoptysis {40.59%}. 
Squamous cell carcinoma (51.82%) was the most common histology 
followed by small cell carcinoma (19.14%). adenocarcinoma (13.86%). 
large cell carcinoma (7.28%). Right lung was effective more and the 
upper lobes were the common sites of involvement.
Conclusion: This study correlates and sometimes differs with the data 
of studies at home and abroad. But reﬂects at least some clinical and 
pathological aspects of bronchial carcinoma in Bangladesh.
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Background: The human epidermal growth factor receptor (HER) 
family of receptor tyrosine kinase has been demonstrated to be overex-
pressed in the majority of NSCLC, leading to the clinical development 
of molecular therapies targeting the epidermal growth factor receptor 
(EGFR). Among the various small molecule inhibitors of tyrosine ki-
nase, geﬁtinib has been approved for clinical use in patients with previ-
ously treated advanced NSCLC. It has shown dramatic effectiveness 
in certain patient subsets, including women, never-smokers, adeno-
carcinomas, and East Asian descents. However, predictive molecular 
markers are yet to be determined. 
Design: EGFR protein overexpression by immunohistochemistry and 
gene ampliﬁcation by chromogenic in situ hybridization (CISH) were 
analyzed in biopsy specimens from 46 patients with advanced NSCLC. 
After failure of ﬁrst-line treatment, 29 had received geﬁtinib. Time 
to progression (TTP) and overall survival (OS) were correlated with 
EGFR status.
